Christopher P. Molineaux of Life Sciences Pennsylvania outlines the Keystone State’s rich lineage of pharmaceutical innovation, how the association is building inter-state and international connections, and why Philadelphia is justified in branding itself as the ‘Cellicon Valley’.
We are at the epicentre of cell and gene therapy, what we are calling ‘Cellicon Valley’. Nowhere else boasts such a concentration of cell and gene therapy manufacturing expertise in one place
Stephen J. Ubl, President & CEO of Pharmaceutical Research and Manufacturers of America (PhRMA) discusses the organisation’s initiatives to address health inequity in the US along with its opposition to…
Cyril Konto, President & CEO of Ichnos Sciences comments on the company’s unique approach to finding new cancer treatments, the possibility of becoming fully independent from parent company Glenmark Pharmaceuticals…
Dan Leonard, President and CEO of the Association for Accessible Medicines (AAM) and Erik C. Komendant, the organisation’s Senior Vice President of Government Affairs, spoke to us about drug pricing…
Pharma companies have become vocal about social issues in recent years, championing access and affordability and launching initiatives to address diversity, but in the weeks since the United States’ Supreme…
Monica Weldon draws on her own experience as a rare disease patient advocacy group CEO to outline how such groups can work collaboratively with other stakeholders in drug development to…
US generics giant Mallinckrodt, which declared bankruptcy in 2020 after a stream of litigation regarding its role in the opioid epidemic and underpaying Medicaid rebates for its drug Acthar, has…
See our Cookie Privacy Policy Here